Ann: International Post-approval Clinical Trial commences, page-5

IPD has been a darling of the analysts but to date has really disapointed in sales growth of the L-Dex system and therefore its share price.

http://www.*.com.au/23-australian-biotech-stocks-to-watch-this-year-2014-2

For eg. Scott Power of Morgans has this on his high conviction list and Bioshares have tipped it.

We know Category 1 coding in the US  should boost sales growth through direct reimbursement but how much? And clinical trials have been going for ever it seems to prove the economics of pre-emptive testing.

Give lacklustre performance to date makes it really tough to average down.  Perhaps closer to the end of the year if we continue to track sideways?